Redeye comments on Faron’s announcement of the final terms of its previously communicated rights issue. The company plans to raise approximately EUR40m in gross proceeds through a fully committed and guaranteed offering at a subscription price of EUR0.50 per share. The terms are broadly in line with our previous estimates, and the proceeds are intended to fund the continued development of bexmarilimab.
LÄS MER
